Nasdaq exas.
Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.53%. At the same ...
35,260.96. +172.67. 【日本経済新聞】エグザクト・サイエンシズ/EXACT Sciences [EXAS] の株価、チャート、業績推移、会社概要、ニュースなど米国株投資や ...Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...EXACT Sciences Corporation stock price live 67.03, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote.The public float for EXAS is 179.16M, and currently, short sellers hold a 4.07% ratio of that floaft. The average trading volume of EXAS on November 30, 2023 was 1.42M shares. EXAS) stock’s latest price update. Exact Sciences Corp. (NASDAQ: EXAS)’s stock price has increased by 0.14 compared to its previous closing price of 64.97.
Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewha... Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last qu...Dec. 1, 2023, 07:35 AM. Leerink Partners analyst Puneet Souda maintained a Buy rating on Exact Sciences ( EXAS – Research Report) yesterday and set a price target of $115.00. …Web
As of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The average price target represents an increase of ...Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...
Exact Sciences (NASDAQ: EXAS) produces and sells diagnostic and cancer screening tests.The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Market Activity Funds + ETFs After-Hours Quotes News + Insights P/E & PEG Ratios Nasdaq MarketSIte Do Not Sell My Personal Information (CA Residents Only) © 2022, …WebNov 17, 2023 · Close $61.17 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing... Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ...
TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.
May 15, 2023 · Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ...
Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Education. You are performing scenario analysis on Exact Sciences Corp. (NASDAQ: EXAS). You know the Food and Drug Administration's (FDA) Advisory Committee will release their report soon, which provides a recommendation as to whether the company's new colon cancer diagnostics test, Cologuard, should be approved by the …After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ...On March 9, 2023, Citigroup upgraded their outlook for EXACT Sciences (NASDAQ:EXAS) from Neutral to Buy.. Analyst Price Forecast Suggests 15.57% Upside. As of March 9, 2023, the average one-year ...EXACT Sciences Corporation stock price live 67.03, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote.Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.
Find out the direct holders, institutional holders and mutual fund holders for Exact Sciences Corporation (EXAS).Exact Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off last year's report dates. Learn more on EXAS's earnings history.Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stockAccording to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ... MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...
Nov 4, 2023 · Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.45) EPS for the quarter, beating ...
Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ... Get the latest Exact Sciences Corporation (EXAS) stock news and headlines to help you in your trading and investing decisions.EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...15.19M. 127.60%. Get the latest Exact Sciences Corp (EXAS) real-time quote, historical performance, charts, and other financial information to help you make more informed …WebOn March 9, 2023, Citigroup upgraded their outlook for EXACT Sciences (NASDAQ:EXAS) from Neutral to Buy.. Analyst Price Forecast Suggests 15.57% Upside. As of March 9, 2023, the average one-year ...At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new August 26th contracts and identified one put and one call contract of particular interest ...
Exact Sciences' CEO is Kevin Conroy, appointed in Apr 2009, has a tenure of 14.58 years. total yearly compensation is $14.22M, comprised of 3.6% salary and 96.4% bonuses, including company stock and options. directly owns 0.68% of …
Exact Sciences Corporation’s EXAS legacy Screening business is witnessing significant improvement, buoyed by Cologuard volume growth. However, escalating costs and stiff competition are concerning.
First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...One company well positioned in this space to benefit from this coming of (middle) age is Exact Sciences ( NASDAQ: EXAS ). The company, founded in the mid-1990s, specializes in diagnostics for ...Nov 20, 2023 · Still, here are two companies that could pull it off: Exact Sciences ( EXAS 0.37%) and Airbnb ( ABNB 1.75%). Let's consider why these two innovative businesses could turn $1,000 into $2,000 by the ... Find the latest analyst research for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona.The …Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript Operator: Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call.Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Exact Sciences Corp ( NASDAQ:EXAS) is working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients worldwide. The company has reported a net ...
Oct 8, 2023 · Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ... 11 Okt 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.Instagram:https://instagram. best forex trading robotstock market big moversoptions in irabanks that work with bankruptcies for home loans EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ... ccaas market share12 month treasury 9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ... m1 crypto Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...One company well positioned in this space to benefit from this coming of (middle) age is Exact Sciences ( NASDAQ: EXAS ). The company, founded in the mid-1990s, specializes in diagnostics for ...Share $67.49 Nov 29, 10:10:29 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Apple Inc $191.11 AAPL0.37% Pacific Biosciences of California Inc $8.85 PACB2.55% Amazon.com Inc $147.18...